Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $29.3 million.

  • Mimedx's Cash from Operations rose 4944.71% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.8 million, marking a year-over-year increase of 1772.22%. This contributed to the annual value of $67.1 million for FY2024, which is 9214.01% up from last year.
  • Per Mimedx's latest filing, its Cash from Operations stood at $29.3 million for Q3 2025, which was up 4944.71% from $14.4 million recorded in Q2 2025.
  • Mimedx's 5-year Cash from Operations high stood at $29.3 million for Q3 2025, and its period low was -$11.1 million during Q4 2021.
  • In the last 5 years, Mimedx's Cash from Operations had a median value of $6.3 million in 2021 and averaged $6.5 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 28793.0% in 2022, then surged by 126600.63% in 2023.
  • Over the past 5 years, Mimedx's Cash from Operations (Quarter) stood at -$11.1 million in 2021, then soared by 49.44% to -$5.6 million in 2022, then skyrocketed by 264.83% to $9.3 million in 2023, then soared by 102.6% to $18.8 million in 2024, then skyrocketed by 56.16% to $29.3 million in 2025.
  • Its last three reported values are $29.3 million in Q3 2025, $14.4 million for Q2 2025, and $5.3 million during Q1 2025.